News | February 06, 2026
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The newly certified kits are designed for early detection and large-scale screening programs
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Subscribe To Our Newsletter & Stay Updated
